Atea Positive Initial Data from Phase 2 Study for Hepatitis C Virus, Enrollment Milestone for Phase 3 Trial for COVID-19

 A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study

Phase 3 SUNRISE-3 Enrollment Surpassed 650 Patients in Monotherapy Arm; First Interim Analysis by the Independent Data Safety Monitoring Board (DSMB) Expected in March 2024

https://www.globenewswire.com/news-release/2024/01/08/2805848/0/en/Atea-Pharmaceuticals-Announces-Positive-Initial-Data-from-Phase-2-Study-for-Hepatitis-C-Virus-HCV-and-Significant-Enrollment-Milestone-for-Phase-3-SUNRISE-3-Trial-for-COVID-19.html